Drug Target for Cancer: HDAC5

Drug Targets for Cancer: HDAC5 and Cancer

Histone deacetylases (HDACs) are enzymes that function in epigenetic gene regulation through chromatin modification. Among 18 human HDACs, HDAC5 (a class IIa HDAC) has been found to contribute to dynamic activities such as synoviocyte activation, neural regeneration and repair, and myoblast differentiation. Recent studies have reported the aberrant overexpression of HDAC5 in hepatocellular carcinoma and high-risk medulloblastoma, whereas HDAC5 downregulation has been reported in colon cancer and is associated with poor prognosis in lung cancer patients. Moreover, Peixoto et al. demonstrated that HDAC5 maintains pericentric heterochromatin structures in human cancer cells and thus represents a potential anticancer drug target.

Drug Targets for Cancer: HDAC5 related Products

Other vital drug targets for cancer like HDAC5:

Drug Targets for Cancer: HDAC5 Related Reference

Li A, et al. HDAC5, a potential therapeutic target and prognostic biomarker, promotes proliferation, invasion and migration in human breast cancer. Oncotarget. 2016;7(25):37966-37978.

Drug Targets for Cancer: HDAC5 Related Information